Entering the Era of Non-Basic P1 Site Groups: Discovery of Xarelto™ (Rivaroxaban)

Author(s): Alexander Straub, Susanne Roehrig, Alexander Hillisch

Journal Name: Current Topics in Medicinal Chemistry

Volume 10 , Issue 3 , 2010

Become EABM
Become Reviewer


Several clinical candidates have now emerged as a result of an intense search for orally available, antithrombotic factor Xa inhibitors. This review highlights the discovery of Xarelto™ (Rivaroxaban) starting from an initial tetrahydrophthalimide screening hit. The major breakthrough was the finding that a chlorothiophene moiety can undergo an interaction in the S1 binding site thus leading to high potency combined with favorable oral bioavailability. The binding mode of this P1 moiety is discussed, and further non-basic S1 binders of this new type are reviewed.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [257 - 269]
Pages: 13
DOI: 10.2174/156802610790725506
Price: $65

Article Metrics

PDF: 38